Home / Resources / Videos / ADA 2018 / Lisa Latts Part 5, Watson Cardiovascular Analysis

Lisa Latts Part 5, Watson Cardiovascular Analysis

In part 5 of this Exclusive Interview, Lisa Latts talks with Diabetes in Control Publisher Steve Freed about the findings from the cardiovascular study for use in Watson.

Lisa Latts MD, MSPH, MBA, FACP is Deputy Chief Health Officer for IBM Watson Health.


Transcript of this video segment:

Freed: So, how does the cardiovascular aspect of it work?

Latts: So, for the cardiovascular study, we looked at the different classes of drugs and we looked at in the year after someone was first prescribed these drugs, what happened to them from a cardiovascular standpoint; were they hospitalized for a heart attack, were they hospitalized for stroke, did they develop a diagnosis of congestive heart failure. And then, we group the classes together and so we acknowledge that there might be some drugs within a class better than others. And we were just looking at the whole classes and what we found is that both the DPP4 class and the SGLT2 inhibitor class had lower or fewer cardiovascular adverse events than the other classes of diabetes drugs. So, both of these from our study at least seem to be cardioprotective as a class effect than the other classes of diabetes drugs.

Freed: And how does a physician or family practitioner use it?

Latts: So, I think there’s a couple of ways. One is that if you have someone who either has cardiovascular disease or is at strong risk for cardiovascular disease maybe besides their diabetes, they’ve got a strong family history, they’ve got high cholesterol that you’re having trouble getting down. And as you mentioned earlier there are so many individual decisions that you have to make in choosing a class of diabetes agents for your patients, having this information may help tip you over to — my patients at risk for cardiovascular disease, I may choose something that perhaps will confer some cardioprotectivity and go for one of these classes of drugs to help me inform my choice.

Freed: It sounds like it’s kind of general information helping you to make a decision as to what drug to use. As I mentioned earlier, is it ever going to get down to the point where it can actually recommend or give you a couple of recommendations? And I know for some physicians that could be tough because you’re taking their knowledge and their ability to make the decision away from them.

Latts: Yeah, yeah.

Freed: And that could be a little scary.

Latts: Absolutely. And Watson is never going to make the decision. Watson is only going to make recommendations based on the best available knowledge. There are so much information being created today. It’s been estimated that 90% of the digital information out there was created in the last two years. And so, when you think about that there’s no way that a human can keep track of all that data and all that information. So, the idea behind Watson is that you make it easier for individuals to access the information that they need at the time that they need it. And so, that’s what it’s going to do, is surface the right information at the right time to help clinicians make the right or better informed decision for their patients.

Return to the main page.